Showing 661-670 of 1376 results for "".
- Lullage Launches Skincare for White Patcheshttps://modernaesthetics.com/news/lullage-launches-skincare-for-white-patches/2473282/Lullage has launched Repigment12 White Patches Corrector Face & Body Cream containing proprietary Repigma12 peptide, a blend of 12 amino acids that provides an innovative mechanism to help restore skin's natural tone. The formula, which took more than five years of development, was c
- Study Assesses What Makes Lips Most Attractivehttps://modernaesthetics.com/news/study-assesses-what-makes-lips-most-attractive/2473273/Although social media and celebrity icons are driving increased demand for fuller, "pouty" lips, a new study in the August issue of Plastic and Reconstructive Surgery found a natural-looking and harmonious app
- AIVA Launches IV Hydration Therapy Business Academy Eventshttps://modernaesthetics.com/news/aiva-launches-iv-hydration-therapy-business-academy-events/2473270/The American IV Association (AIVA) is launching two IV Hydration Therapy Business Academy events to assist anyone getting into the IV hydration therapy business, adding IV hydration therapy to an existing practice, or those looking to grow their existing practice. Each one-day even
- Evolus Seeks Eternal Love in New “Switch Your Tox” Campaignhttps://modernaesthetics.com/news/evolus-seeks-eternal-love-in-new-switch-your-tox-campaign/2473269/With its new “Switch Your Tox and Love Evolus Forever” campaign, Evolus Inc. is encouraging consumers to try its flagship neurotoxin product, Jeuveau® (prabotulinumtoxinA-xvfs). As part of the promotion, participating injectors get discount vouchers totaling $160 for two cons
- BTL Launches EMSCULPT NEO Edge Applicator for the Lateral Abdomenhttps://modernaesthetics.com/news/btl-launches-emsculpt-neo-edge-applicator-for-the-lateral-abdomen/2473265/BTL is launching the new Edge™ Applicators to treat the entire lateral abdomen. Shipping will begin in
- FDA Nod for Sientra’s Low Plus Profile Projection Breast Implanthttps://modernaesthetics.com/news/fda-nod-for-sientras-low-plus-profile-projection-breast-implant-1/2473263/The U.S. Food and Drug Administration (FDA) approved Sientra’s Low Plus Profile Projection Breast Implant for breast augmentation in women at least 22 years old, and for women of all ages undergoing breast reconstruction. This product will be commercially available for board-certi
- Cynosure Launches Innovative Tempsure eyeEnvi Handpiece with Improved Function and Greater Comforthttps://modernaesthetics.com/news/cynosure-launches-innovative-tempsure-eyeenvi-handpiece-with-improved-function-and-greater-comfort/2473262/Cynosure's new Tempsure eyeEnvi handpiece features innovative ergonomic pencil grip design and lighter piston tension required to activate the treatment, making it more comfortable for both patient and provider, heating thinner tissue more effectively and comfortably while minimizin
- Katie Glowski Joins Living Proof as Chief Sales Officerhttps://modernaesthetics.com/news/katie-glowski-joins-living-proof-as-chief-sales-officer/2473258/Katie Glowski is now Chief Sales Officer at Living Proof. She has more than 25 years of brand management and sales experience across integrated marketing, sales strategy, financial operations, and talent development. “I am thrilled to join the
- Crown Laboratories, Inc.'s Announces Leadership Team Growthhttps://modernaesthetics.com/news/crown-laboratories-incs-annouces-leadership-team-growth/2473256/Joe Proctor and Michael McKenna are stepping into new roles at Crown Laboratories. Joe Proctor will transition from General Manager, Aesthetics into the Head of Innovation and Corporate Development for Crown Aesthetics. Mr. Proctor is the founder of Crown
- Top-line Phase 3 Data Promising for Galderma's RelabotulinumtoxinAhttps://modernaesthetics.com/news/top-line-phase-3-data-promising-for-galdermas-relabotulinumtoxina/2473250/Galderma’s investigational RelabotulinumtoxinA, a novel liquid formulation botulinum toxin A, improves both glabellar and lateral canthal lines with a rapid onset of action and a long duration up to six months, according to top-line phase 3 data presen